The Yield Growth Corp. (Stock: BOSQF) offers investors ability at a rapidly-growing market
News Hit The Wires 6-18-2020: BOSQF Files Patent Application for Therapeutic Use of DMT
Strong News hit The Wires: BOSQF Announced Filing for a U.S. Provisional Patent
The potential health benefits associated with psilocybin mushrooms has triggered rapid growth in the space…and in the midst of this rapidly growing market, one company has moved quickly to position itself to take maximum advantage.
That company is The Yield Growth Corp. (Stock: BOSQF) a vertically integrated company that develops, licenses and sells plant-based products, formulas and conducts research into plant-based medicine in the $4.2 trillion global wellness market.
The Psilocybin Mushroom Market is
Poised for Significant Growth
The psilocybin mushroom market right now stands poised for significant potential growth thanks to three critical factors:
1) A growing push toward legalization, with California and Colorado leading the way in the United States…
2) Mounting scientific evidence showing the health benefits of psilocybin mushrooms, including the potential to help treat serious illnesses…
3) An increasing awareness in the mainstream media – including films, books and media personalities – of the potential health benefits associated with psilocybin mushrooms, which is helping bring nationwide legalization closer to reality.
To build on its success in the legal hemp and cannabis markets, The Yield Growth Corp. is now actively pursuing research and market opportunities in the psilocybin mushroom market.
The Yield Growth Corp. Has Moved Quickly to Establish an Early Leadership Position
The Yield Growth Corp. (Stock: BOSQF) has taken several significant steps to establish an early leadership position in the rapidly-growing psilocybin mushroom market, including establishing a majority-owned subsidiary – NeonMind Biosciences Inc.
The company aims to be a leader in the fast-growing functional foods market by offering high-quality mushroom-infused products that support immune, cognitive, memory and other brain functions.
NeonMind Biosciences holds the global rights to a robust catalog of more than 145 product formulations for infusion with functional mushrooms. The company intends to develop mushroom-infused, ready-to-eat packaged food products which promote health and wellness in the following categories:
· Beverages: teas, lattes and hot cocoas
· Meals: soups
· Desserts and confections: chocolate, truffles and bliss balls
· Mixes and elixir: a variety of flavors to add to the food or drink of consumer’s choice.
NeonMind Biosciences has already achieved several key milestones, including:
· Filing a U.S. provisional patent application to protect the invention that the administration of psilocin and/or psilocybin results in overall weight loss in individuals by reducing food cravings, counteracting compulsive overeating, improving quality of diet, increasing metabolism, treating diabetes, regulating blood glucose and reducing susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus and other illnesses associated with obesity.
· Acquired approximately 18% of Translational Life Sciences Inc., which aims to develop proprietary formulations using restricted substances to focus on unmet medical needs in opioid dependence, psychotic illness, pain management and traumatic brain injury, including concussion. The company also offers services to design and oversee clinical trials of restricted substances such as psilocybin based formulations for third parties.
· And on May 7, 2020 the company announced that NeonMind had entered into an agreement with Transitional Life Sciences Inc. to initiate clinical trials to test certain potential therapeutic effects of psilocybin and other compounds in psychedelic mushrooms. The companies will work together to conduct the evaluation of psilocin or psilocybin on cravings, on the metabolism, on food addiction and on glucose and hormone levels.
The Translational Life Sciences team is comprised of physicians and scientists who are recognized thought leaders in the fields of Neurology, Pharmacology, Pain Management, Addiction and Biochemistry and have significant experience in the clinical application of cannabinoid compounds.
These moves appear to be just the beginning of the steps The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) is taking in order to establish a strong early presence in the rapidly growing psilocybin mushroom space.
Widespread North American Movement Underway to Decriminalize Psychedelic Mushrooms
According to the Financial Post, cannabis legalization has set a strong precedent for magic mushrooms.
In May 2019, Denver, Colorado voted to decriminalize mushrooms that contain psilocybin, and Oakland California did the same a few weeks later. The state of Oregon is working to do the same for 2020.
And in October 2019, the U.S. FDA granted “breakthrough therapy” status to a London-based company to test psilocybin for treatment-resistant depression.
This trend toward legalization is growing rapidly: Vice reports that there is a growing lobby dedicated to advocating for psychedelics – and that they are well-organized and well-funded. Of course, this growing legalization movement is happening for good reason…
Psilocybin Mushrooms Have Shown the Potential for Significant Health Benefits
The health results that have been achieved worldwide with the support of psychedelics have caused a growing number of people to take notice.
Anecdotal evidence linking psilocybin to potential treatments for serious diseases goes back centuries.
And now modern science is confirming a number of important health benefits that have triggered explosive growth in the market.
For example, researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post.
And studies have shown that psilocybin could provide effective treatment for things like depression, alcohol addiction and many other psychological disorders.
· Johns Hopkins Medicine recently announced the launch of a Center for Psychedelic and Consciousness Research, with $17 million in capital earmarked for studying psychedelics.
· That announcement from Johns Hopkins came on the heels of Imperial College London’s launch of a similar center backed by $3.5 million in private donations.
· And the University of Toronto has opened its Centre for Psychedelic Studies, which will host the world’s first clinical trials on microdosing psilocybin.
A Closer Look at the Investment Potential in the Psilocybin Mushroom Market
Here’s why the increase of science-backed evidence supporting the health benefits of psilocybin mushrooms offers a high-upside investment opportunity:
The global antidepressant drug market was valued at $13.7 billion in 2016 and is projected to grow to $15.9 billion by 2023.
One hundred million of those diagnosed with major depressive disorder (MDD) are said to suffer from treatment-resistant depression (TRD). This accounts for approximately 33% of MDD cases.
The FDA decision to fast track the testing of psilocybin could allow for psychedelic mushrooms to penetrate this market. Psychedelic mushrooms represent an exciting new opportunity for companies that can capitalize on cutting edge science and technology.
That makes the steps The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) has already taken critically important, as the company works to become among the first publicly traded companies to establish legal production and distribution of psilocybin for medical research.
Rapid Rollout of Hand Sanitizer to Help Meet the Needs of Consumers During Global Pandemic
In addition to its recent advances in the psilocybin mushroom space, The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) is also working to meet the global needs when it comes to preventing the spread of the coronavirus.
A number of companies have stepped up to help fight this global pandemic, moving quickly to adapt on the fly and deliver supplies just as they are needed the most.
The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) is also leading the way when it comes to this battle, as it just received approval from Health Canada for the production of liquid hand sanitizer.
On March 27, the company announced that its subsidiary, Urban Juve, earned approval for hand sanitizer liquid spray manufacturing, within just one week of its application being submitted.
In addition, the company announced that on April 2 it received approval from Health Canada for a second product; a hand sanitizer gel and announced its FDA approval in the U.S. on April 23.
These fast track approvals will allow the company to complete a rapid initial manufacturing run which could translate into the direct sale to customers via the Urbanjuve.com web site within the next 30 days.
All packaging and raw materials have been secured for the initial production run and the company also plans to file an application with the FDA in order to sell hand sanitizer in the United States.
According to Reportsnreports.com, the global market for hand sanitizers is anticipated to reach $5.5 billion by 2024, up from $2.4 billion in 2017. CNBC also reported that sales of hand sanitizers increased by 470% in the first week of March this year compared to the same week a year earlier.
Urban Juve’s natural hand sanitizer liquid spray contains 65% alcohol, which is in line with Health Canada guidelines, and also has a refreshing and clean blend of peppermint, lavender and orange peel oils, all of which are known for their disinfecting properties and their ability to promote optimum skin health.
“I’m so impressed with the speed and efficiency with which Health Canada handled our application,” said Yield Growth Corp. CEO Penny White. “We are tremendously thankful to all of the policy makers in Canada and all around the world who are working tirelessly to come up with policies to fight the health and economic crisis at hand.”
“With two different formulas approved,” White continued, “we have more packaging options, which will allow us to complete additional manufacturing runs to better meet the urgent and unprecedented demand for products that limit the spread of COVID-19.”
Yield Growth intends to donate a portion of the hand sanitizers that it manufactures to workers on the front line. Yield Growth has already been donating self-care products to front line workers with over 500 products delivered to senior centers in the immediate area.
The company is a leader in bringing hemp and cannabis-infused products to the cannabis-infused luxury wellness market in a way that connects ancient healing with modern science.
The Yield Growth Corp. has over 200 proprietary beauty, wellness, edibles and beverage formulas for commercialization. It has filed 13 patents to protect its extraction methods and formulas. Yield Growth earns revenue through multiple streams including licensing, services and product sales.
By bringing cannabis to the luxury wellness market, The Yield Growth Corp. is serving a market filled with mainstream luxury consumers in search of sophisticated wellness products.
The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) is a vertically-integrated company that currently has access to multiple revenue streams via its subsidiary companies, including: Urban Juve Provisions, Inc.
· Direct to consumer sales within Canada and the U.S. via e-commerce site
· Retail distribution agreements with more than 110 brick and mortar stores across North America since the beginning of 2019
Wright & Well Essentials Inc.
· Now launching 9 THC products into the Oregon market under the brand Wright & Well
Jack N Jane
· Drawing on the wisdom of ancient Ayurveda apothecaries, Jack n Jane unlocks the vast potential of the cannabis plant with a premium line of THC and CBD-infused products including tinctures, topicals and capsules. Using high-quality cannabis ingredients from Apothecary Botanicals, Jack n Jane is poised to serve the growing market within Canada.
UJ Beverages Inc.
· Line of eight wellness beverage formulas to be infused with CBD and THC and one capsule product intended to treat hangovers
Yield Botanicals Inc.
· Proprietary patent pending extraction technology combining Ayurveda therapeutic extraction methods with modern science and commercial hemp root oil production
Thrive Activations Inc.
· Provides management personnel and expertise to small and growing companies
The Yield Growth Corp. Well-Positioned to Deliver High Upside Potential to Investors
Investors looking for exposure to the rapidly-growing psilocybin mushroom space should consider The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) while the company is still below Wall Street’s radar.
With significant potential industry growth, a “Hall of Fame” level management team of experienced executives and a significant first-to-market advantage, The Yield Growth Corp. (CSE: BOSS); (OTCQB: BOSQF); (Frankfurt:YG3) appears well positioned for the months and years ahead.
The Yield Growth Corp’s highly experienced leadership team is made up of proven leaders with extensive backgrounds and success stories from a variety of relevant industries, including…
Co-Founder, President & CEO, Director
Penny is a serial entrepreneur and
securities lawyer with over two decades of experience in online music,
international film distribution, mobile payments, blockchain technology,
crowdsourcing, renewable energy, pharmaceuticals, e-commerce and cannabis. She
is also co-founder of Merus Labs Inc. (TSX:MSL, NASDAQ:MSLI-Q), which was
acquired by Norgine B.V. in 2017 for $342 million. Penny was recognized in
PROFIT Magazine’s W100 most successful entrepreneurs and included in PROFIT 500
Fastest Growing companies in 2015 and 2016.
Chief Operating Officer, The Yield Growth Corp.
Among her career achievements, Tamara was
instrumental in the growth of Canadian fashion retailer Aritzia (TSX:ATZ) as
its Vice President, Corporate Operations and Executive Vice President, People
& Culture. When she joined in 2001, Aritzia had 10 stores and 30 head
office employees, and Melck built several of the corporate backend functions
from scratch, helping Aritzia to scale its operations and achieve $743M in
annual revenue and to reach a market capitalization of over $1 billion when she
left in 2017.
Melck was a member and former chair of
the Executive Committee of Aritzia, and she directly led and oversaw numerous
departmental and cross-functional projects of all sizes to build the necessary
infrastructure to enable growth. Aritzia is a vertically integrated, innovative
design house of exclusive fashion brands. It reported net revenue of $743.3
million in Fiscal 2018.
Jeff B. Smith
Chairman of the Advisory Board, The Yield Growth Corp.
Jeff Smith was the Global Chief Transformation Officer at Johnson & Johnson Consumer Companies, the world’s largest and most diversified healthcare company with worldwide sales of US$76 billion in 2017.
In his most recent role as Johnson & Johnson Company Group Chairman for Consumer North America, Jeff delivered strong organic growth, new growth levers such as Beauty Special Ops and the OceanX partnership, and oversaw several important strategic acquisitions including Vogue International LLC, La Lumière, and Neostrata. His division represented more than 42% of global revenue, delivering over US$6.5 billion in annual revenue with mid-single digit growth rates; spent over US$1 billion in marketing investment; delivered consistent market share gains and doubled the regional profitability. Jeff was on the Johnson & Johnson’s Group Operating Committee Executive.
Prior to acting as Chairman of Johnson & Johnson, in 2011 Jeff was appointed President, U.S. Skincare in the newly formed North American region. Jeff had full P&L responsibility for the Baby (JOHNSON’S®, AVEENO®) and Beauty Care divisions (NEUTROGENA®, AVEENO®, CLEAN & CLEAR®, LUBRIDERM® and KORRES® Natural products) within the United States. As President of Johnson & Johnson’s largest business unit, Jeff grew it from the third-largest skincare company to #1 in the U.S. over 3.5 years.
Vice President Licensing & General Counsel, The Yield Growth Corp.
Amy Frankel has over 15 years of
experience working with consumer product companies. In her various roles as
in-house counsel, Amy has gained vast experience building, protecting and
expanding international brands. Previously, Amy was Co-General Counsel of
Aritzia LP (TSX: ATZ) and Associate General Counsel of Skechers USA Inc. (NYSE:
SKX). During her time at Skechers, annual revenues increased approximately 50%
($675M to $1.006B) and the share price increased over 300%. During her time at
Aritzia, annual revenues increased approximately 100%, from under $400M to
$743M. Her expertise includes negotiating inbound and outbound licensing deals,
developing intellectual property strategies, and managing international intellectual
property portfolios. Amy’s experience also includes corporate governance for
private and public US and Canadian companies, as well as a wide breadth of
commercial matters, including distribution agreements and technology contracts.
Amy began her career as a business
litigator in Los Angeles, appearing before numerous state and federal courts
before moving in-house with Skechers. Amy practiced law in California for 10
years prior to moving to Vancouver, BC. In 2008, she was admitted to the Law
Society of British Columbia. Amy obtained her Bachelor’s degree from the
University of California, Santa Barbara and her Juris Doctorate from the
University of California, Hastings. She is licensed in California and British
CFO, The Yield Growth Corp.
Rick Huang served as CFO of Hanwei Energy Services corporation (TSX: HE). Rick has also served as CFO of several other publicly traded companies, where he has managed all aspects of finance, banking, compliance, accounting, reporting, internal control, admin, and supporting the board of directors in financial oversight. He also has supervised all aspects of accounting for various subsidiary companies in Canada, China, Russia and Kazakhstan and consolidations under IFRS.
He has worked on investor relations activities, roadshow AGM preparations, and licensing agreements and has led various public equity financing projects raising funds of up to $90 million and leading acquisitions of up to $80 million. Rick has negotiated for international joint ventures, including drafting shareholders’ agreements, establishing international legal entities, and assets transfers. Rick also serves as Chair of the Audit Committee for Datable Technology Corp. (TSXV: TTM) and previously Chair of the Governance Committee and member of the Audit Committee of Poydras Gaming Finance Corp. (TSXV: PYD)
REAL TIME MARKET NEWS & UPDATES “Get A Leg Up On Your Competition!” Stay Connected With What Could Be The Fastest News Dissemination Service.
Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 6/8/20 and ending on 6/30/20 to publicly disseminate information about (BOSS) via digital communications. We have been paid an additional ten thousand USD via bank wire transfer. We own zero shares of (BOSS). To date we have been paid thirty five thousand five hundred dollars USD via bank wire transfer to disseminate information about (BOSS) via digital communications.